Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Common Equity (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Common Equity over the past 12 years, most recently at $722.2 million for Q4 2025.

  • Quarterly results put Common Equity at $722.2 million for Q4 2025, up 7.52% from a year ago — trailing twelve months through Dec 2025 was $722.2 million (up 7.52% YoY), and the annual figure for FY2025 was $722.2 million, up 7.52%.
  • Common Equity for Q4 2025 was $722.2 million at Viridian Therapeutics, Inc.\DE, up from $503.0 million in the prior quarter.
  • Over the last five years, Common Equity for VRDN hit a ceiling of $722.2 million in Q4 2025 and a floor of $98.9 million in Q2 2021.
  • Median Common Equity over the past 5 years was $402.0 million (2022), compared with a mean of $396.9 million.
  • Biggest five-year swings in Common Equity: soared 872.3% in 2021 and later plummeted 30.67% in 2023.
  • Viridian Therapeutics, Inc.\DE's Common Equity stood at $187.7 million in 2021, then surged by 110.46% to $395.1 million in 2022, then grew by 11.89% to $442.0 million in 2023, then surged by 51.95% to $671.6 million in 2024, then rose by 7.52% to $722.2 million in 2025.
  • The last three reported values for Common Equity were $722.2 million (Q4 2025), $503.0 million (Q3 2025), and $515.2 million (Q2 2025) per Business Quant data.